Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study

References

• Global initiative for chronic Obstructive Lung Disease (GOLD)Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2010 updateGlobal Initiative for Chronic Obstructive Lung Disease, Inc2010 Available from: http://www.goldcopd.org/uploads/users/files/GOLDReport_April112011.pdfAccessed on July 20, 2012
   Google Scholar
• KarnerCCatesCJLong-acting beta(2)-agonist in addition to tiotro-pium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease [review]Cochrane Database Syst Rev20124CD00898922513969
   PubMed Web of Science ®Google Scholar
• MahlerDAD’UrzoABatemanEDINTRUST-1 and INTRUST-2 study investigatorsConcurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparisonThorax201267978178822544891
   PubMed Web of Science ®Google Scholar
• RabeKFTimmerWSagkriotisAVielKComparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPDChest2008134225526218403672
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBRDecramerMLystigTLiuDKestenSEfficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trialCOPD20129328929622432932
   PubMedGoogle Scholar
• van NoordJAAumannJLJanssensEComparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J200526221422216055868
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEEffects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPDChest2006129350951716537846
   PubMed Web of Science ®Google Scholar
• van NoordJABuhlRLaforceCQVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary diseaseThorax201065121086109120978028
   PubMed Web of Science ®Google Scholar
• SzmidtMThe influence of treatment with formoterol, formoterol with tiotropium, formoterol with inhaled glucocorticosteroid and tiotropium on lung functions, tolerance of exercise and simple, morning everyday activities in patients with chronic obstructive pulmonary disease (COPD)Pneumonol Alergol Pol2012803255262 Polish [with English abstract]22562275
   PubMedGoogle Scholar
• YuAPGuérinAPonce de LeonDTherapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalersJ Med Econ201114448649621679019
   PubMedGoogle Scholar
• BeehKMSinghDDi ScalaLDrollmannAOnce-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trialInt J Chron Obstruct Pulmon Dis2012750351322973092
   PubMed Web of Science ®Google Scholar
• D’UrzoAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res20111215622151296
   PubMed Web of Science ®Google Scholar
• DahlRChungKFBuhlRINVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study InvestigatorsEfficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDThorax20106547347920522841
   PubMed Web of Science ®Google Scholar
• FeldmanGSilerTPrasadNINLIGHT 1 study groupEfficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week studyBMC Pulm Med2010101120211002
   PubMed Web of Science ®Google Scholar
• KerwinEHébertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
   PubMed Web of Science ®Google Scholar
• KornmannODahlRCentanniSINLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-μg Doses with COPD Patients) study investigatorsOnce-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparisonEur Respir J201137227327920693243
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J Epub2013530
   Web of Science ®Google Scholar
• DahlRChapmanKRRudolfMSafety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN studyRespir Med2013107101558156723867808
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol – fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Resp Med2013115160
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHSandstormTTaylorAFDual bronchodilator treatment for the prevention of exacerbations of chronic obstructive pulmonary disease: the SPARK StudyLancet Resp Med20131199209
   PubMed Web of Science ®Google Scholar
• MahlerDADecramerMD’UrzoASuperior lung function with once-daily QVA149 translates into improvements in patient-reported breathlessness compared with placebo and tiotropium in COPD patients: the BLAZE studyAm J Respir Crit Care Med2013187A6070
   Web of Science ®Google Scholar
• Novartis PharmaceuticalsComparison of safety and efficacy of the combination product QVA149 A against the concurrent administration of the individual components, QAB149 and NVA237, in patients with chronic obstructive pulmonary disease (COPD) (BEACON) Available from: http://clinicaltrials.gov/ct2/show/NCT1529632. NLM identifier: NCT1529632Accessed August 23, 2013
   Google Scholar
• Novartis PharmaceuticalsEfficacy and safety of QVA149 in patients with chronic obstructive pulmonary disease (COPD) Available from: http://www.clinicaltrials.gov/ct2/show/NCT0570778?term=NCT0570778&rank=1. NLM identifier: NCT0570778Accessed February 25, 2013
   Google Scholar
• CazzolaMTashkinDPCombination of formoterol and tiotro-pium in the treatment of COPD: effects on lung functionCOPD20096540441519863370
   PubMedGoogle Scholar
• BertonDCReisMSiqueiraACEffects of tiotropium and for-moterol on dynamic hyperinflation and exercise endurance in COPDRespir Med201010491288129620580216
   PubMed Web of Science ®Google Scholar
• JonesPWDonohueJFNedelmanJPascoeSPinaultGLassenCCorrelating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysisRespir Res20111216122206353
   PubMed Web of Science ®Google Scholar
• AntónEHow and when to use inhaled corticosteroids in chronic obstructive pulmonary disease?Expert Rev Respir Med20137Suppl 2253223551021
   PubMed Web of Science ®Google Scholar
• Van de MaeleBFabbriLMMartinCHortonRDolkerMOverendTCardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patientsCOPD20107641842721166630
   PubMedGoogle Scholar
• CarreiroASantosJRodriguesFImpact of comorbidities in pulmonary rehabilitation outcomes in patients with chronic obstructive pulmonary diseaseRev Port Pneumol2013193106113 Portuguese [with English abstract]23664247
   PubMed Web of Science ®Google Scholar